Seroprevalence of antibodies against SARS-Cov-2 in the high impacted sub-district in Jakarta, Indonesia.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2021
2021
Historique:
received:
20
09
2021
accepted:
14
12
2021
entrez:
23
12
2021
pubmed:
24
12
2021
medline:
27
1
2022
Statut:
epublish
Résumé
Understanding the actual prevalence of COVID-19 transmission in the community is vital for strategic responses to the pandemic. This study aims to estimate the actual infection of COVID-19 through a seroprevalence survey and to predict infection fatality rate (IFR) in Tanjung Priok, the hardest-hit sub-district by the COVID-19 in Jakarta, Indonesia. We conducted a venous blood sampling (phlebotomy) to 3,196 individuals in Tanjung Priok between Nov 23, 2020, and Feb 19, 2021 to detect their antibodies against SARS-CoV-2. Using an enumerator-administered questionnaire, we collected data on the respondents' demographic characteristics, COVID-19 test history, COVID-19 symptoms in the last 14 days, comorbidities, and protective behaviours during the last month. We employed descriptive analysis to estimate the seroprevalence and IFR. The prevalence of Antibody against SARS-CoV-2 was 28.52% (95% CI 25.44-31.81%), with the result being higher in females than males (OR 1.20; 95% CI 1.02-1.42). By the end of the data collection (February 9, 2021), the cumulative cases of COVID-19 in Tanjung Priok were reported to be experienced by 9,861 people (2.4%). Those aged 45-65 were more likely to be seropositive than 15-19 years old (OR 1.42; 95% CI 1.05-1.92). Nearly one third (31%) of the subjects who developed at least one COVID-19 symptom in the last 14 days of the data collection were seropositive. The estimated IFR was 0.08% (95% CI 0.07-0.09), with a higher figure recorded in males (0.09; 95% CI 0.08-0.10) than females (0.07; 95% CI 0.06-0.08), and oldest age group (45-65) (0.21; 95% CI 0.18-0.23) than other younger groups. An under-reporting issue was found between the estimated COVID-19 seroprevalence and the reported cumulative cases in Tanjung Priok. More efforts are required to amplify epidemiological surveillance by the provincial and local governments.
Sections du résumé
BACKGROUND
Understanding the actual prevalence of COVID-19 transmission in the community is vital for strategic responses to the pandemic. This study aims to estimate the actual infection of COVID-19 through a seroprevalence survey and to predict infection fatality rate (IFR) in Tanjung Priok, the hardest-hit sub-district by the COVID-19 in Jakarta, Indonesia.
METHODS
We conducted a venous blood sampling (phlebotomy) to 3,196 individuals in Tanjung Priok between Nov 23, 2020, and Feb 19, 2021 to detect their antibodies against SARS-CoV-2. Using an enumerator-administered questionnaire, we collected data on the respondents' demographic characteristics, COVID-19 test history, COVID-19 symptoms in the last 14 days, comorbidities, and protective behaviours during the last month. We employed descriptive analysis to estimate the seroprevalence and IFR.
FINDINGS
The prevalence of Antibody against SARS-CoV-2 was 28.52% (95% CI 25.44-31.81%), with the result being higher in females than males (OR 1.20; 95% CI 1.02-1.42). By the end of the data collection (February 9, 2021), the cumulative cases of COVID-19 in Tanjung Priok were reported to be experienced by 9,861 people (2.4%). Those aged 45-65 were more likely to be seropositive than 15-19 years old (OR 1.42; 95% CI 1.05-1.92). Nearly one third (31%) of the subjects who developed at least one COVID-19 symptom in the last 14 days of the data collection were seropositive. The estimated IFR was 0.08% (95% CI 0.07-0.09), with a higher figure recorded in males (0.09; 95% CI 0.08-0.10) than females (0.07; 95% CI 0.06-0.08), and oldest age group (45-65) (0.21; 95% CI 0.18-0.23) than other younger groups.
CONCLUSION
An under-reporting issue was found between the estimated COVID-19 seroprevalence and the reported cumulative cases in Tanjung Priok. More efforts are required to amplify epidemiological surveillance by the provincial and local governments.
Identifiants
pubmed: 34941968
doi: 10.1371/journal.pone.0261931
pii: PONE-D-21-30389
pmc: PMC8699601
doi:
Substances chimiques
Antibodies, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0261931Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Geroscience. 2020 Aug;42(4):1063-1074
pubmed: 32677025
PLoS One. 2021 Mar 23;16(3):e0249090
pubmed: 33755688
Prog Disaster Sci. 2020 Apr;6:100091
pubmed: 34171011
Ann Intern Med. 2020 Sep 1;173(5):362-367
pubmed: 32491919
Appl Psychol Health Well Being. 2020 Dec;12(4):1183-1204
pubmed: 32981212
Sci Rep. 2021 Mar 18;11(1):6233
pubmed: 33737535
Int J Environ Res Public Health. 2021 Feb 16;18(4):
pubmed: 33669412
PLoS One. 2021 May 6;16(5):e0251234
pubmed: 33956869
BMC Med. 2020 Oct 22;18(1):332
pubmed: 33087179
PLoS One. 2021 Jun 23;16(6):e0252617
pubmed: 34161316
Emerg Infect Dis. 2021 Feb;27(2):636-638
pubmed: 33349310
J Glob Health. 2020 Dec;10(2):020306
pubmed: 33110510
Bull World Health Organ. 2021 Jan 1;99(1):19-33F
pubmed: 33716331
Nat Rev Genet. 2021 Jul;22(7):415-426
pubmed: 33948037
Clin Microbiol Infect. 2021 Apr;27(4):633.e1-633.e7
pubmed: 33253941
Lancet Public Health. 2021 Apr;6(4):e202-e209
pubmed: 33556328
J Public Health (Oxf). 2021 Apr 12;43(1):e112
pubmed: 32894290
PLoS One. 2021 Apr 2;16(4):e0248946
pubmed: 33798211
BMJ. 2020 Nov 27;371:m4509
pubmed: 33246972
BMC Med. 2021 Jun 18;19(1):146
pubmed: 34144715
Front Public Health. 2020 Aug 13;8:473
pubmed: 32903584